Date:2021.6.8 Your Name: Zhongxi Shen Manuscript Title: Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Huzhou Public Welfare	
	manuscript (e.g., funding,	Research Project Social	
	provision of study materials,	Development (Key Medical	
	medical writing, article	and Health) Category (No.	
	processing charges, etc.)	2018GZ39)	
	No time limit for this item.	Huzhou Public Welfare	
		Research Project Social	
		Development Category	
		(2018GYB49)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	
		(No. LGF19H090003)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	

		(No. LGF19H090002)	
		Time frame: pas	t 26 months
2	Grants or contracts from	None	
2	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
10	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name: Feng Wang Manuscript Title: Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Huzhou Public Welfare	
	manuscript (e.g., funding,	Research Project Social	
	provision of study materials,	Development (Key Medical	
	medical writing, article	and Health) Category (No.	
	processing charges, etc.)	2018GZ39)	
	No time limit for this item.	Huzhou Public Welfare	
		Research Project Social	
		Development Category	
		(2018GYB49)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	
		(No. LGF19H090003)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	

		(No. LGF19H090002)	
		Time frame: pas	t 26 months
2	Grants or contracts from	None	
2	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
10	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name: Lijun Cui Manuscript Title:Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Huzhou Public Welfare	
	manuscript (e.g., funding,	Research Project Social	
	provision of study materials,	Development (Key Medical	
	medical writing, article	and Health) Category (No.	
	processing charges, etc.)	2018GZ39)	
	No time limit for this item.	Huzhou Public Welfare	
		Research Project Social	
		Development Category	
		(2018GYB49)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	
		(No. LGF19H090003)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	

		(No. LGF19H090002)	
		Time frame: pas	t 26 months
2	Grants or contracts from	None	
2	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
10	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name: Lie Ren Manuscript Title: Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Huzhou Public Welfare	
	manuscript (e.g., funding,	Research Project Social	
	provision of study materials,	Development (Key Medical	
	medical writing, article	and Health) Category (No.	
	processing charges, etc.)	2018GZ39)	
	No time limit for this item.	Huzhou Public Welfare	
		Research Project Social	
		Development Category	
		(2018GYB49)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	
		(No. LGF19H090003)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	

		(No. LGF19H090002)	
		Time frame: pas	t 26 months
2	Grants or contracts from	None	
2	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
0	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
10	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name: Xiujuan Hong Manuscript Title: Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39) Huzhou Public Welfare Research Project Social Development Category (2018GYB49) Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003) Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019	

		(No. LGF19H090002)	
		T '	
2	Grants or contracts from	Time frame: pas	t 36 months
2	any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
	,		
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name:Yonggui Yuan Manuscript Title:Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	Huzhou Public Welfare	
	manuscript (e.g., funding,	Research Project Social	
	provision of study materials,	Development (Key Medical	
	medical writing, article	and Health) Category (No.	
	processing charges, etc.)	2018GZ39)	
	No time limit for this item.	Huzhou Public Welfare	
		Research Project Social	
		Development Category	
		(2018GYB49)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	
		(No. LGF19H090003)	
		Social Development	
		Project of Public Welfare	
		Technology Application in	
		Zhejiang Province in 2019	

		(No. LGF19H090002)	
		T '	
2	Grants or contracts from	Time frame: pas	t 36 months
2	any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
	,		
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The author has no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.6.8 Your Name: Xinhua Shen Manuscript Title :Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present	Huzhou Public Welfare			
	manuscript (e.g., funding,	Research Project Social			
	provision of study materials,	Development (Key Medical			
	medical writing, article	and Health) Category (No.			
	processing charges, etc.)	2018GZ39)			
	No time limit for this item.	Huzhou Public Welfare			
		Research Project Social			
		Development Category			
		(2018GYB49)			
		Social Development			
		Project of Public Welfare			
		Technology Application in			
		Zhejiang Province in 2019			
		(No. LGF19H090003)			
		Social Development			
		Project of Public Welfare			
		Technology Application in			
		Zhejiang Province in 2019			

		(No. LGF19H090002)	
			
2	Grants or contracts from	Time frame: pas	t 36 months
2	any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	None	
	,		
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The author reported that this study was partly supported by funds from the Huzhou Public Welfare Research Project Social Development (Key Medical and Health) Category (No. 2018GZ39 to Xinhua Shen), Huzhou Public Welfare Research Project Social Development Category (2018GYB49, Zhongxia Shen), the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090003 to Xinhua Shen), and the Social Development Project of Public Welfare Technology Application in Zhejiang Province in 2019 (No. LGF19H090002 to Zhongxia Shen). The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: